Oct 11, 2012, 11.32 AM | Source: Moneycontrol.com
Microsec is bullish on GlaxoSmithKline Consumer Healthcare and has recommended buy rating on the stock with a target of Rs 3642 in its October 10, 2012 research report.
, Microsec |
“GlaxoSmithKline Consumer Healthcare plans to spend Rs 250 crore in CY12E and Rs 150 crore in CY13E towards expanding its existing capacities. Part of the expansion plan will be completed in Q3 CY12E and the total expansion will be completed by June 2013 at its Sonepat, Haryana plant. This will boost the topline in the coming 3 years time. Rural markets have low penetration levels of around 11 per cent in Malted Health Food Drinks category compared with the 40 per cent levels of urban markets. Growing income levels and low awareness present an opportunity to the company to penetrate it higher.”
“GSK Consumer has undertaken price hike in Horlicks and Boost (i.e. from INR162 to INR171/500g pack) at the end of July 2012 which will help it in keeping its margin intact and protect it against the rising raw- material prices. GSK Consumer has pricing power for its products as it is evident from its stable margin in the range of 18-19% in last 5 Yrs. With the introduction of new range of products like Horlicks Gold, Women Horlicks, Junior Horlicks and aggressive advertisment compaign in media, we expect the volume growth of 8-9% to be back on track by the end of CY12E. As it is said in cricket that “Form is temporary, class is permanent”, the same is applied to the volume growth of GSK Consumer which we believe will bounce back and sustain for long term in india once the form returns.”
“At the CMP of INR2977 the stock discounts its CY12E EPS of INR102.3 by 29.1x and its CY13E EPS of INR125.6 by 23.7x. With Established Brand like Horlicks, Boost, Maltova and Viva, Strong ROE, Stable EBITDA Margin and Focus on Health & Nutrients, the prospect of the company appears to be good for long term. We assign a P/E multiple of 29x to its CY13E EPS of INR125.6 to arrive at the target price of INR3642 for the stock,” says Microsec research report.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click here
GlaxoSmithKline Consumer Healthcare Ltd today repo
The company had posted net profit of Rs 156.05 cro
Net Sales are expected to up 2 percent Y-o-Y to Rs